Cue BiopharmaCUE -0.28%59 Buyback Yield % is -26.13 as of Jul. 03, 2026. GuruFocus rates CUE with a GF Score™ of 59/100 and a GF Value™ of $62.36 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 744 Biotechnology companies, Cue Biopharma ranks worse than 73.52% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Cue Biopharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CUE vs ALPS, AARD, KLRS: Buyback Yield % Comparison
For the Biotechnology subindustry, Cue Biopharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma (CUE) has a Buyback Yield % of -26.13 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cue Biopharma and its competitors. According to the industry distribution chart, Cue Biopharma ranks #547 out of 744 companies in the Biotechnology industry, placing it in the top 73.5%.
Is Cue Biopharma's Buyback Yield % too high?
Cue Biopharma's current Buyback Yield % is -26.13. Based on the distribution chart, Cue Biopharma ranks #547 out of 744 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Buyback Yield % compare to ALPS and AARD?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #547 out of 744 companies for Buyback Yield %. This places Cue Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current Buyback Yield % is -26.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.36, compared to a current price of $28.33 — trading 54.6% below its estimated fair value. The current Buyback Yield % is -26.13. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Buyback Yield % is -26.13 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cue Biopharma (CUE) Overvalued in 2026?
Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued.
The current stock price of $28.33 is trading 54.6% below its estimated GF Value™ of $62.36.
GuruFocus considers Cue Biopharma to be Possible Value Trap.
Key valuation signals for CUE:
Buyback Yield %: -26.13
GF Value™: $62.36 vs. price of $28.33 (54.6% below fair value)
No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score
Get the complete analysis for CUE
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUE has been successfully added to your 
